课题基金 / 基金详情

Software for Predicting Liver Injury from Biologics Drug Candidates Using Data from a Human Liver Microphysiology System

Software for Predicting Liver Injury from Biologics Drug Candidates Using Data from a Human Liver Microphysiology System
使用人类肝脏微生理学系统的数据预测生物制剂候选药物肝损伤的软件
批准号:
10248834
负责人:
Brett Alyn Howell
金额:
$10.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-03-01 至 2021-09-01

项目摘要

项目成果

Brett Alyn Howell的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The goal of this project is to develop novel technology for predicting biologics-induced liver injury such as caused by anti-inflammatory biologics such as anti-IL6 receptor antibody (e.g., tocilizumab), and by growth factors such as neuregulin-1β isoform, glial growth factor 2 (GGF2), as well as by other biologics (e.g., checkpoint inhibitors). Biologics now account for more than half of the drugs in development, and have the potential to address many acute diseases, chronic diseases, and other unmet medical needs. Biologics-induced liver injury can manifest as focal hepatocyte necrosis, steatosis, and fibrosis. In some cases, liver transplantation is required for patients with biologics-induced liver injury. A significant problem is that while there is increased development and use of biologics, there lacks tools available for the assessment of biologics for the ability to cause biologics-induced liver injury. For example, because biologics are typically designed specifically for human targets, standard preclinical models used for small molecule drug development are inadequate for assessing the efficacy or safety of biologics. In this project, we will develop novel technology that will serve as a prototype for use in testing biologics (preclinical, clinical, or after-market) for potential to cause biologics-induced liver injury. In developing this new technology, we will also further develop the state-of-the-art human liver MPS (vLAMPS) to assess the liver effects of biologics from human liver cells in the liver acinus with the aim of using vLAMPS as the eventual key source of input data for BIOLOGXsym simulations. Additionally, we will perform validation of this new technology. Once validated, this system will serve as a prototype that can then be expanded for commercialization for use by our existing base of pharmaceutical company customers, regulatory agencies, and academic institutions for teaching and academic research use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Software for Predicting Liver Injury from Biologics Drug Candidates Using Data from a Human Liver Microphysiology System
  • 批准号:
    10520293
  • 项目类别:
  • 资助金额:
    $14.46万
  • 财政年份:
    2021
  • 负责人:
    Brett Alyn Howell
  • 依托单位:
海外基金